27.05.2013 - A survey of European clinical geneticists show that a vast majority reject direct-to-consumer (DTC) genetic testing without prior face-to-face counselling.
According to the survey, carried out by Heidi Carmen Howard from French INSERM and Pascal Borry from KU Leuven among 131 EU geneticists, DCT testing for monogenetic and complex diseases is more widespread than thought before. 44% of patients who asked their doctor for genetic counselling, had previously already undertaken a DCT test (Genome Medicine). However, the respondents seem concerned about the DCT test offers. 84% of them disagreed with replacing face-to-face supervision by a medical doctor with supervision via telephone, which is offered by some DTC testing firms. Over 85% of respondents said that they would offer genetic counselling to patients who asked for a consultation after having undergone DTC genetic testing
A majority of clinical geneticists also found it unacceptable to provide non-face-to-face medical supervision for: a pre-symptomatic test for a condition with very high penetrance; a predictive test for a condition that has a “medium” penetrance of 50 to 60%; and for carrier testing. For conditions that are neither treatable nor preventable and for disorders with serious health consequences, clinical geneticists were almost unanimous in expressing the unacceptability of offering such genetic tests outside of the traditional health care setting, without an established physician-patient relationship and without face-to-face medical supervision.
Recently, the German Ethics Council tabled recommendations on genetic diagnosis to the government asking for international rules for DCT testing and a duty to have face-to-face counselling before any of those tests. According to the survey, patients need qualified information on clinical significance, medical relevance and validity of such tests.
15.09.2014 Jean Claude Juncker, the European Commission President-elect revealed his new Commissioners last week, whilst announcing a change in the units dealing with medicines, medical devices and health technology.
12.09.2014 The 2011 collaboration of Boehringer Ingelheim and Eli Lilly is bearing fruit. An insulin biosimilar developed through the partnership has now been approved in Europe - the first-ever generic version of this class.
09.09.2014 In the midst of the hustle and bustle of the European Respiratory Society’s International Congress 2014, Astrazeneca quietly announced the disappointing results of its latest benralizumab study.
29.08.2014 Just a week ago, Glaxosmithkline defused the WHO’s claim that an Ebola vaccine could be ready by 2015. Now, the British company’s own candidate vaccine is to be rushed to human trials with the help of funding from an international consortium.
24.08.2014 Germany's Morphosys is licensing a preclinical bi-specific antibody for the treatment of prostate cancer from Emergent Biosolutions. The US developer will rake in up to €138m for the commercialisation rights to the compound.
20.08.2014 Biopharmaceutical contract manufacturer Fujifilm Diosynth Biotechnologies is expanding its cell culture manufacturing capacity further with a new 2,000l single-use bioreactor at the company’s site in Billingham, UK.